ライフサイエンスコーパス: influenza

1 e randomized, and 501 were confirmed to have influenza.

2 y occurred among IC adults hospitalized with influenza.

3 sponse of the elderly to the vaccine against influenza.

4 d prevalence of antibiotic prescriptions and influenza.

5 ains (HKU1, 229E, OC43) and three strains of influenza.

6 smosis (14.0%) and blastomycosis (13.1%) vs. influenza (20.2%).

7 mong 89 999 adults with laboratory-confirmed influenza, 80 261 had complete medical record abstractio

8 respiratory viruses, including an assay for influenza A (FluA) virus, influenza B (FluB) virus, and

9 challenge studies used the identical lot of influenza A (H1N1)pdm09 virus administered intranasally.

10 iruses detected by routine clinical testing (influenza A [n = 3], human metapneumovirus [n = 2], and

11 15 and 2018, a total of 335 index cases with influenza A and 1,506 of their household contacts were e

12 oxil (BXM) was approved in 2018 for treating influenza A and B virus infections.

13 the relatively conserved stalk region of the influenza A hemagglutinin (HA) surface protein.

14 Unlike influenza A M2 (AM2), which conducts protons with strong

15 lucidate the critical role of isotype for an influenza A monoclonal antibody therapeutic.

16 3 further enables comprehensive subtyping of influenza A strains and multiplexed identification of do

17 Targeting hemagglutinin from influenza A to Clec9A induced Ab responses with higher a

18 In the absence of a universal influenza A vaccine or treatment, influenza A will remai

19 Recognition of influenza A virus (IAV) by the innate immune system trig

20 Influenza A virus (IAV) causes a wide range of extraresp

21 erged lineage of human-like H3N2 (H3.2010.1) influenza A virus (IAV) from swine has been frequently d

22 grade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells.

23 ys an essential role in host defense against influenza A virus (IAV) infection.

24 pact on host-to-host transmission.IMPORTANCE Influenza A virus (IAV) infections are important threats

25 Influenza A virus (IAV) is a lytic RNA virus that trigge

26 The viral ribonucleoprotein (vRNP) of the influenza A virus (IAV) is responsible for the viral RNA

27 For enveloped viruses, such as the influenza A virus (IAV), large N-linked glycans can also

28 Influenza A virus (IAV)-related mortality is often due t

29 The influenza A virus deploys this strategy to bind strongly

30 netic diversity than previously observed for influenza A virus during acute infections.

31 Comparing SARS-CoV-2 and influenza A virus in human airway epithelial cultures, w

32 In a disease context, influenza A virus infection impaired AM crawling via the

33 PORTANCE Successful zoonotic transmission of influenza A virus into humans can lead to pandemics in a

34 ce using coinfection with 1 x 10(4.5) PFU of influenza A virus MEM H3N2, followed by intranasal chall

35 cation in cells, prevented death in a lethal influenza A virus mouse challenge model, and dramaticall

36 igate its global propensity to interact with influenza A virus polymerase.

37 l number of factors required for restricting influenza A virus replication.

38 , including that infection with a particular influenza A virus should offer long-term or lifelong pro

39 responses in mice to two naturally presented influenza A virus-derived peptides previously identified

40 t transmission bottleneck similar to that of influenza A virus.

41 (TLR4, TLR1/2, and TLR7/8) or infection with influenza A virus.

42 icular, yet remains understudied compared to influenza A virus.

43 rototypical lab-adapted strains of the human influenza A virus.

44 n and reduced its antiviral activity against Influenza A virus.

45 976 of waterfowl as the primary reservoir of influenza A viruses (IAVs) has since spurred decades of

46 nza outbreaks of 1918 and 2009, subtype H1N1 influenza A viruses (IAVs) have caused seasonal epidemic

47 Novel H1N2 influenza A viruses (IAVs) in swine have been identified

48 Swine influenza A viruses (swIAVs) can play a crucial role in

49 ent a vast reservoir from which new pandemic influenza A viruses can emerge(1).

50 Influenza A viruses continue to circulate among wild bir

51 Moreover, influenza A viruses that are transmissible via the air p

52 , as they are in the HA protein of mammalian influenza A viruses.

53 smissibility, and interspecies adaptation of influenza A viruses.

54 universal influenza A vaccine or treatment, influenza A will remain a significant threat to human he

55 ratory distress syndrome (ARDS) secondary to influenza A(H1N1) infection and 10 age-matched, uninfect

56 This is the case for human-origin influenza A(H1N1) pandemic 2009 (pdm09) viruses detected

57 oligotypes on susceptibility differ between influenza A(H3N2) and B viruses.

58 % (95% CrI, 0.5-42%) lower susceptibility to influenza A(H3N2) infection, respectively.

59 henotypes.IMPORTANCE Highly pathogenic avian influenza A(H5N1) viruses have circulated continuously i

60 indings suggest that the higher virulence of influenza A(H5N8) viruses from the 2016-17 outbreak may

61 In 2016, influenza A(H5N8) viruses were reintroduced into the Net

62 ation of primary duck cells with recombinant influenza A(H5N8) viruses, including viruses with reasso

63 (M2e-MAbs) show protective potential against influenza A, however, they are either strain specific or

64 No patient tested positive for influenza A, influenza B, or other respiratory viruses.

65 uman PBMC culture, and increased survival of influenza A-infected mice.

66 ntly by viruses, primarily morbillivirus and influenza A.

67 Here we report the isolation of the influenza A/H1N1 2009 pandemic (A/H1N1pdm) and A/H3N2 vi

68 nged due to the emergence and circulation of influenza A/H1N1pdm09.

69 lu Trends) data for situational awareness of influenza across poverty levels.

70 th further increases in coverage and reduced influenza across the community.

71 Disease Control and Prevention (CDC) tracks influenza activity through a national surveillance netwo

72 f recovery in older adults hospitalized with influenza and acute respiratory illness.

73 s in patients with bacterial etiology versus influenza and CAP versus normal.

74 they somehow clear infection by coronavirus, influenza and LCMV in vivo.

75 irectly transmitted human pathogens, such as influenza and measles, generate sustained exponential gr

76 r improved vaccines and therapeutics against influenza and one such target is the relatively conserve

77 on of relatively small amounts of three anti-influenza antibodies.

78 Improved understanding of influenza antigen structure and immunobiology is advanci

79 Influenza antigens may undergo adaptive mutations during

80 tory infection or febrile illness (ARFI) and influenza-associated ARFI among pregnant women, administ

81 A large proportion of the influenza-associated burden occurs among young infants a

82 nation in older adults, who account for most influenza-associated deaths annually.

83 Around 50,000 influenza-associated deaths occur annually in the U.S.,

84 atients who died from Covid-19-associated or influenza-associated respiratory failure, the histologic

85 Among 891 276 adults, 2435 influenza-associated SARI hospitalizations occurred.

86 uding an assay for influenza A (FluA) virus, influenza B (FluB) virus, and respiratory syncytial viru

87 H3N2 and influenza B titers were similar between seasons.

88 Influenza B virus is a serious health concern for childr

89 We studied how the within-host diversity of influenza B virus relates to its global evolution by seq

90 No patient tested positive for influenza A, influenza B, or other respiratory viruses.

91 g data from samples from 91 individuals with influenza B, we find that IBV accumulates lower genetic

92 In this influenza B-Victoria and A(H1N1)-dominated season, RIV4

93 to substantial additional reductions in the influenza burden in the United States.

94 Moreover, the influenza burden might have changed due to the emergence

95 eport cryo-electron microscopy structures of influenza C virus polymerase (FluPolC) in complex with h

96 Infection with influenza can be aggravated by bacterial co-infections,

97 cinating 50%-70% of school-aged children for influenza can produce population-wide indirect effects.

98 ost-influenza season sera from PCR-confirmed influenza cases (n = 50), and (ii) an immunology cohort,

99 Each year in the United States, influenza causes illness in 9.2 to 35.6 million individu

100 Influenza contributes significantly to childhood morbidi

101 Since its detection in swine, influenza D virus (IDV) has been shown to be present in

102 Experimental results on three influenza datasets show that Tempel can significantly en

103 endas, we aimed to quantify the magnitude of influenza disease that would be prevented through target

104 is study, we profiled resistance to the anti-influenza drug laninamivir in AIVs with substitutions kn

105 dults hospitalized with laboratory-confirmed influenza during 2011-2015 seasons through CDC's Influen

106 specimens collected from patients tested for influenza during the 2010-11 to 2015-16 influenza season

107 s are important in controlling infections by influenza, Ebola, or HIV-1 in animal models.

108 eficiency virus (HIV) infection, malaria and influenza, effective vaccinations are still lacking.

109 ic mutations that allow immune escape impact influenza epidemic dynamics at the population level.

110 sed environmental and virological drivers of influenza epidemics.

111 isparities in vaccination rates for seasonal influenza exist.

112 In contrast, influenza-experienced resident AMs remain largely simila

113 patients are at a higher risk for developing influenza (flu)- related complications.

114 travel flows, and use this model to generate influenza forecasts in conjunction with incidence data f

115 Previously, we discovered that influenza-generated CD4 effectors must recognize cognate

116 e comparison of the variant viruses to swine influenza genomes.

117 h have been implicated in protection against influenza, have yet to be defined.

118 (Newcastle disease, Lyme disease), trimers (influenza hemagglutinins), and tetramers (influenza neur

119 tries tailored to present the ectodomains of influenza, HIV, and RSV viral glycoprotein trimers.

120 uenza during 2011-2015 seasons through CDC's Influenza Hospitalization Surveillance Network.

121 potential risk factor for increased rates of influenza hospitalizations and ED visits.

122 Highly pathogenic avian influenza (HPAI) is a devastating disease of poultry and

123 Highly pathogenic avian influenza (HPAI) viruses of the H5 A/goose/Guangdong/1/9

124 Here we report that Fc engineering of anti-influenza IgG monoclonal antibodies for selective bindin

125 talk regions) and neuraminidase (NA), impact influenza illness and virus transmission.

126 Severe influenza illness is presumed more common in adults with

127 tive cohort of human subjects with confirmed influenza illness of varying severity who presented with

128 portant evidence for maternal and paediatric influenza immunisation, and should inform future immunis

129 e simulate transmission dynamics of seasonal influenza in England from 2012 to 2018.

130 stalk domain (H1/stalk) following trivalent influenza inactivated vaccine (IIV3) immunization in pre

131 ith emerging evidence of the consequences of influenza-induced changes in metabolic homeostasis on di

132 kine production by MDMs or PBECs but reduced influenza-induced IL-1beta production by PBECs.

133 Influenza infection causes substantial morbidity and mor

134 ut cell-mediated immune responses to natural influenza infection in solid organ transplant (SOT) pati

135 traction of lung CD8+ T cell responses after influenza infection is contemporized with egress of CD69

136 ine activity localized to EVs which inhibits influenza infection of ECs in vitro and in vivo.

137 ntly circulating strains.IMPORTANCE Seasonal influenza infection remains a major cause of disease and

138 Influenza infection reveals the emergence of a populatio

139 acebo arm (P =; .34) in those with confirmed influenza infection.

140 powered to evaluate vaccine efficacy against influenza infection.

141 ective population size of infection N(e) for influenza infection.

142 ults are at increased risk of mortality from influenza infections.

143 Influenza is difficult to distinguish clinically from ot

144 enza viruses, a future pandemic caused by H2 influenza is likely.

145 ng behavior of FNY participants who reported influenza-like illness (ILI) symptoms.

146 f SARS-CoV-2 (n = 224) and of non-SARS-CoV-2 influenza-like illness (n = 184), and laboratory-confirm

147 e probably associated with similar risks for influenza-like illness and laboratory-confirmed viral in

148 tients aged 1 year and older presenting with influenza-like illness in primary care.

149 Primary care patients with influenza-like illness treated with oseltamivir recovere

150 nd significantly shortened symptom duration (influenza-like illness, 82%; 95% CI, 39-95%).

151 e and visited weekly to detect pneumonia and influenza-like illness.

152 swabs collected from patients in Wuhan with influenza-like-illness from 6 October 2019 to 21 January

153 pitalized immunocompromised (IC) adults with influenza may have worse outcomes than hospitalized non-

154 We propose that the pig influenza model will be useful for testing candidate mAb

155 e binding kinetics of antiviral drugs to the influenza neuraminidase.

156 s (influenza hemagglutinins), and tetramers (influenza neuraminidases).

157 ons and emergency department (ED) visits for influenza or culture-negative pneumonia from 2005 to 201

158 In addition to causing the pandemic influenza outbreaks of 1918 and 2009, subtype H1N1 influ

159 susceptibility to infection or on non-severe influenza outcomes.

160 ., all-cause, respiratory, and pneumonia and influenza, (P&I)].

161 nd memory CD4+ T cell repertoire against the influenza pandemic H1 hemagglutinin (H1-HA).

162 italised with COVID-19 and compare them with influenza patients.

163 tbreaks as well as common infections such as influenza persist as a health threat.

164 r influenza viruses, 614 (58%) of which were influenza positive.

165 mong 37 487 ARI outpatients, 9659 (26%) were influenza positive.

166 All ARTI diagnoses but influenza predicted receiving systemic steroids.

167 s for ATAAD during months with above average influenza rates.

168 The extent to which influenza recurrence depends upon waning immunity from p

169 ntial for rapid and broad protection against influenza reinfection.

170 There was a lower incidence of influenza-related complications in the pimodivir group (

171 in previously immunocompetent children with influenza-related critical illness and is associated wit

172 Seasonal influenza vaccines prevent influenza-related illnesses, hospitalizations, and death

173 the ability to differentiate and can support influenza replication and isolation.

174 37 (35%) tested positive for one or more non-influenza respiratory viruses.

175 a virus and on the factors known to increase influenza risk infection leading to organ failure and de

176 rosurvey cohort, consisting of pre- and post-influenza season sera from PCR-confirmed influenza cases

177 hool absences per 100 school days during the influenza season was -0.63 (95% CI -1.14, -0.13; p = 0.0

178 In the 2017-2018 influenza season, quadrivalent, inactivated cell-derived

179 oughout an eight-week sampling period during influenza season.

180 l of the United States to simulate different influenza seasons and the impact of reducing the variabi

181 aky, we simulated the 2011-2012 to 2014-2015 influenza seasons to estimate the potential contribution

182 for influenza during the 2010-11 to 2015-16 influenza seasons.

183 st evidence that hyperglycaemia may increase influenza severity by damaging the pulmonary epithelial-

184 ted functional characteristics comparable to influenza-specific CD8(+) T cells and were detectable in

185 an inverse correlation between pre-existing influenza-specific salivary IgA concentrations and tonsi

186 taining 15 mug of each of the three seasonal influenza strains for that year, as a single dose, a dou

187 d systemic T-cell responses differed between influenza strains, and both were found against H3N2 and

188 using Tennessee Emerging Infections Program Influenza Surveillance data from 2006 to 2016 and the co

189 of IAV vRNP but also provide potential anti-influenza targets for antiviral development.

190 tted in real-time from a national network of influenza test machines called the Influenza Test System

191 l Corporation provided us with de-identified influenza test results transmitted in real-time from a n

192 etwork of influenza test machines called the Influenza Test System (ITS).

193 In the case of influenza, the receptor-binding glycoprotein is the haem

194 While a tight bottleneck operates in human influenza transmission, it is not extreme in nature; som

195 Using a published phylodynamic model of influenza transmission, we identified indicators of futu

196 on ancestral descent, such as in the case of influenza type A hemagglutinin.

197 d highly variable overall contributions from influenza type A viruses across seasons, but relatively

198 tussis-inactivated poliomyelitis-Haemophilus influenza type b-hepatitis B combination vaccine were gi

199 therapeutic treatments of multiple relevant influenza types (H1N1, H3N2, and B) can be achieved by a

200 e most common of which were nasopharyngitis, influenza, upper respiratory tract infection, and headac

201 simulate future trajectories of both RSV and influenza, using an epidemic model.

202 Influenza vaccination and antiviral administration could

203 Because influenza vaccination can be poorly effective some years

204 ns with moderately high background levels of influenza vaccination coverage, SLIV programs are associ

205 ty of germinal centre B cell responses after influenza vaccination in humans.

206 These results support the importance of influenza vaccination in older adults, who account for m

207 nt study does support the protective role of influenza vaccination on CVDs events.

208 3,201 single cells from healthy high and low influenza vaccination responders revealed that our signa

209 t that differences in cross-reactivity after influenza vaccination should be expected in individuals

210 sits and antibiotic prescriptions averted by influenza vaccination using estimates of VE, coverage, a

211 nts enrolled in a clinical trial of maternal influenza vaccination, we estimate incidence of RSV-asso

212 ason, quadrivalent, inactivated cell-derived influenza vaccine (ccIIV4) vaccine was produced using A(

213 -controlled (trivalent high-dose inactivated influenza vaccine [IIV3-HD], or quadrivalent recombinant

214 ccine [IIV3-HD], or quadrivalent recombinant influenza vaccine [RIV4]), safety and immunogenicity tri

215 reducing the variability in responses to the influenza vaccine across the population.

216 d randomisation list, to receive inactivated influenza vaccine containing 15 mug of each of the three

217 e improvements in effectiveness or VC of the influenza vaccine could lead to substantial additional r

218 a statistical model to data from studies of influenza vaccine effectiveness (VE), we find that prima

219 this risk can be attenuated with the annual influenza vaccine in this patient population.

220 Live-attenuated influenza vaccine induces both mucosal and systemic anti

221 Since it is unknown whether influenza vaccine is leaky, we simulated the 2011-2012 t

222 raham pigs, using the single cycle candidate influenza vaccine S-FLU.

223 implementation of a more broadly protective influenza vaccine.

224 The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in r

225 We investigated the RVE of influenza vaccines among Medicare beneficiaries ages >=6

226 effectiveness emphasizes the need for better influenza vaccines and other preventive strategies.

227 To understand how influenza vaccines could be improved, vaccine effectiven

228 This result suggests that cell-derived influenza vaccines may have greater effectiveness than s

229 Seasonal influenza vaccines prevent influenza-related illnesses,

230 AIV4 and injectable, tetravalent inactivated influenza vaccines replacing IIV3.

231 Influenza vaccines represent the most effective response

232 Some antiviral drugs and broadly reactive influenza vaccines that target the HA protein have suffe

233 specifically dedicated to improving seasonal influenza vaccines while developing entirely new vaccine

234 We conducted a test-negative study of influenza VE in community-dwelling older adults with COP

235 o be associated with highly pathogenic avian influenza virus (HPAIV) H5N1 outbreaks in South-East Asi

236 analysis.IMPORTANCE Low-pathogenicity avian influenza virus (LPAIV) subtypes can reassort with circu

237 xicity and virus-inhibiting activity against influenza virus A/Puerto Rico/8/34 (H1N1) in MDCK cell l

238 Influenza virus accounted for 7% of ALRI cases, 5% of AL

239 characterizing a novel restriction factor of influenza virus and may ultimately be useful for underst

240 ed changes in response to infection with the influenza virus and on the factors known to increase inf

241 dy species elicited by previous exposures to influenza virus antigens(4).

242 inhibitory action against various strains of influenza virus as well as the paramyxoviruses PIV5, HPI

243 se structures therefore reveal mechanisms of influenza virus assembly and disassembly.

244 cation termination factor 2 (RTF2) restricts influenza virus at the nuclear stage (and perhaps other

245 me viruses, including Epstein-Barr virus and influenza virus can elicit T cell responses against abno

246 er avidity that more efficiently neutralized influenza virus compared with Xcr1 and DEC-205 targeting

247 We further show that after the swine-origin influenza virus emerged in humans and caused the 2009 pa

248 Strains of the influenza virus form coherent global populations, yet ex

249 ovide evidence that aberrant RNA products of influenza virus genome replication can trigger retinoic

250 found mAbs targeting conserved neutralizing influenza virus hemagglutinin epitopes were polyreactive

251 men, and association with protection against influenza virus illness.

252 tructure of the HA protein of the avian H7N9 influenza virus in complex with a pan-H7, non-neutralizi

253 3-adjuvanted versus nonadjuvanted H5N1 avian influenza virus inactivated vaccine.

254 Future studies need to investigate whether influenza virus infection affects susceptibility for aor

255 us on their impact on T cell motility during influenza virus infection.

256 o associate with lung damage and severity of influenza virus infection.

257 ry-confirmed and antigenically-characterised influenza virus infections from Australia, we investigat

258 ination is the most effective way to prevent influenza virus infections.

259 swine-origin A(H1N1)pdm09 viruses.IMPORTANCE Influenza virus infects a wide range of hosts, resulting

260 or their ability to support the avian-origin influenza virus polymerase.

261 ailable a tool for validating and annotating influenza virus sequences that is used to check submissi

262 y of natural compounds against the following influenza virus strains: A/WSN/33 (H1N1), A/Udorn/72 (H3

263 is needed of how antibodies that target the influenza virus surface antigens, hemagglutinin (HA) (in

264 lear retention of vRNPs and the reduction of influenza virus titers.

265 RTF2 thus inhibits primary influenza virus transcription, likely acts in the nucleu

266 coated with a monovalent, split inactivated influenza virus vaccine containing A/Singapore/GP1908/20

267 bs) derived from B cells induced by numerous influenza virus vaccines and infections, we found mAbs t

268 ase as a potential target of next-generation influenza virus vaccines.

269 For influenza virus, mutational data have shown that the mem

270 levant to human and animal health, including influenza virus, reovirus, HIV-1, human metapneumovirus,

271 models to investigate the mechanisms driving influenza virus-induced inflammation in humans.

272 e glycan epitope high mannose as a marker of influenza virus-induced pathogenesis and severity of dis

273 severity of infection with seasonal or avian influenza virus.

274 bottleneck between humans infected with the influenza virus; however, the methods used to make these

275 mated incidence and hospitalisation rates of influenza-virus-associated respiratory infections by sev

276 y found during OS and ZAN selection in avian influenza viruses (AIVs) of the N3 to N9 subtypes for LA

277 ic acids (Sia) are the primary receptors for influenza viruses and are widely displayed on cell surfa

278 n hospitalized with ARFI who had testing for influenza viruses by reverse-transcription polymerase ch

279 The results suggest swine influenza viruses containing both a stabilized HA and al

280 hat the X-ORFs of equine H3N8 and avian H3N2 influenza viruses encoded 61 amino acids but were trunca

281 clades, while reassortment with other avian influenza viruses has led to the emergence of new virus

282 Bat influenza viruses have not been tested for their virulen

283 ovides insights into the varying dynamics of influenza viruses in human infection.

284 eutic activity against currently circulating influenza viruses in humans.

285 For swine influenza viruses isolated in 2009-2016, gamma-clade vir

286 in Bangladesh, where highly pathogenic avian influenza viruses of the A(H5N1) subtype are endemic and

287 ablished in Vietnam to identify the scope of influenza viruses present in live bird markets and the t

288 to antigenically drifted A(H3N2) clade 3C.3a influenza viruses prompted concerns about vaccine effect

289 The genesis of novel influenza viruses through reassortment poses a continuin

290 tions, 1064 (6%) included RT-PCR testing for influenza viruses, 614 (58%) of which were influenza pos

291 orn after 1968 have not been exposed to H2N2 influenza viruses, a future pandemic caused by H2 influe

292 encoded by many enveloped viruses, including influenza viruses, herpes viruses, and coronaviruses.

293 s become immunodominant in recent human H3N2 influenza viruses, is also evolutionarily constrained by

294 crucial advances for antiviral targeting of influenza viruses.

295 bitor of the polymerase acid (PA) protein of influenza viruses.

296 ruses and cocirculating low-pathogenic avian influenza viruses.

297 s and is the main source of novel pathogenic influenza viruses.

298 btype are endemic and cocirculate with other influenza viruses.

299 ition (HAI) activity against a panel of H1N1 influenza viruses.

300 A likely coinfection with influenza was neither linked to a more severe presentati